MCID: ESP027
MIFTS: 45

Esophagus Squamous Cell Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Esophagus Squamous Cell Carcinoma

MalaCards integrated aliases for Esophagus Squamous Cell Carcinoma:

Name: Esophagus Squamous Cell Carcinoma 12 14
Squamous Cell Carcinoma of Esophagus 12 69
Esophageal Squamous Cell Carcinoma 41
Scc of Esophagus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3748
MeSH 41 C562729
NCIt 46 C4024
SNOMED-CT 64 276804009
UMLS 69 C0279626

Summaries for Esophagus Squamous Cell Carcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial squamous cells located in the esophagus.

MalaCards based summary : Esophagus Squamous Cell Carcinoma, also known as squamous cell carcinoma of esophagus, is related to esophageal cancer and squamous cell carcinoma, and has symptoms including abnormality of the voice, clinodactyly of the 5th toe and nausea and vomiting. An important gene associated with Esophagus Squamous Cell Carcinoma is DSE (Dermatan Sulfate Epimerase), and among its related pathways/superpathways are Cytoskeletal Signaling and DNA Damage. The drugs Aspirin and Irinotecan have been mentioned in the context of this disorder. Affiliated tissues include the esophagus, lymph node and lung, and related phenotypes are cellular and growth/size/body region

Related Diseases for Esophagus Squamous Cell Carcinoma

Diseases related to Esophagus Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 42)
# Related Disease Score Top Affiliating Genes
1 esophageal cancer 31.1 CCND1 CDH1 WWOX
2 squamous cell carcinoma 29.6 CCND1 CDH1 CTTN WWOX
3 esophageal adenosquamous carcinoma 10.1 CDH1 WWOX
4 gastric cardia carcinoma 10.1 CDH1 WWOX
5 ethmoid sinus cancer 10.1 CCND1 CTTN
6 ethmoid sinus adenocarcinoma 10.1 CCND1 CTTN
7 squamous cell carcinoma of the oral tongue 10.0 CCND1 CDH1
8 jejunal adenocarcinoma 10.0 CCND1 WWOX
9 pre-malignant neoplasm 10.0 CCND1 CDH1
10 gastrointestinal system benign neoplasm 10.0 CCND1 CDH1
11 intestinal benign neoplasm 10.0 CCND1 CDH1
12 pharynx cancer 10.0 CCND1 CDH1
13 tongue cancer 10.0 CCND1 CDH1
14 ductal carcinoma in situ 9.9 CCND1 CDH1
15 bile duct carcinoma 9.9 CCND1 CDH1
16 male reproductive organ cancer 9.9 CCND1 CDH1
17 adenoid squamous cell carcinoma 9.9 CDH1 VIM
18 biphasic synovial sarcoma 9.9 CDH1 VIM
19 female reproductive organ cancer 9.9 CCND1 CDH1
20 bladder urothelial carcinoma 9.9 CCND1 CDH1
21 chondroid chordoma 9.9 CDH1 VIM
22 papillary adenocarcinoma 9.8 CDH1 VIM
23 oral cancer 9.8 CCND1 CDH1
24 colorectal adenocarcinoma 9.8
25 adenocarcinoma 9.8
26 lymphopenia 9.8
27 spindle cell carcinoma 9.8 CDH1 VIM
28 intrahepatic cholangiocarcinoma 9.8 CCND1 CDH1
29 hidradenocarcinoma 9.8 CCND1 VIM
30 polymorphous low-grade adenocarcinoma 9.8 CCND1 VIM
31 chondromyxoid fibroma 9.8 CCND1 VIM
32 reproductive organ cancer 9.7 CCND1 CDH1
33 lung cancer susceptibility 3 9.7 CCND1 CDH1 RUNX3
34 oral squamous cell carcinoma 9.7 CCND1 CDH1 CTTN
35 squamous cell carcinoma, head and neck 9.7 CCND1 CDH1 CTTN
36 inflammatory myofibroblastic tumor 9.7 CCND1 VIM
37 sarcoma, synovial 9.7 CDH1 VIM
38 gastrointestinal system cancer 9.7 CCND1 CDH1 WWOX
39 cell type cancer 9.7 CCND1 CDH1 WWOX
40 breast ductal carcinoma 9.5 CCND1 CDH1
41 endometrial stromal sarcoma 9.4 CCND1 VIM
42 salivary gland adenoid cystic carcinoma 9.4 CCND1 CDH1 CTTN RUNX3

Graphical network of the top 20 diseases related to Esophagus Squamous Cell Carcinoma:



Diseases related to Esophagus Squamous Cell Carcinoma

Symptoms & Phenotypes for Esophagus Squamous Cell Carcinoma

Human phenotypes related to Esophagus Squamous Cell Carcinoma:

31 (show all 8)
# Description HPO Frequency HPO Source Accession
1 abnormality of the voice 31 frequent (33%) HP:0001608
2 clinodactyly of the 5th toe 31 hallmark (90%) HP:0001864
3 nausea and vomiting 31 frequent (33%) HP:0002017
4 lymphadenopathy 31 occasional (7.5%) HP:0002716
5 feeding difficulties in infancy 31 hallmark (90%) HP:0008872
6 esophageal carcinoma 31 hallmark (90%) HP:0011459
7 cough 31 frequent (33%) HP:0012735
8 chest pain 31 frequent (33%) HP:0100749

MGI Mouse Phenotypes related to Esophagus Squamous Cell Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.73 CDH1 CTTN RUNX3 VIM WWOX CCND1
2 growth/size/body region MP:0005378 9.63 CCND1 CDH1 CTTN DSE RUNX3 WWOX
3 immune system MP:0005387 9.43 CCND1 CDH1 CTTN RUNX3 VIM WWOX
4 reproductive system MP:0005389 9.1 CCND1 CDH1 CTTN DSE VIM WWOX

Drugs & Therapeutics for Esophagus Squamous Cell Carcinoma

Drugs for Esophagus Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
2
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Capecitabine Approved, Investigational Phase 2, Phase 3, Phase 1 154361-50-9 60953
6
Cetuximab Approved Phase 2, Phase 3, Phase 1 205923-56-4 56842117 2333
7
Oxaliplatin Approved, Investigational Phase 2, Phase 3, Phase 1 61825-94-3 43805 6857599 5310940 9887054
8
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
9
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
10
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
11
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
12
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
13
Vinblastine Approved Phase 3 865-21-4 241903 13342
14
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 44424639 60780
15
Pembrolizumab Approved Phase 3,Phase 2 1374853-91-4
16
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
17
nivolumab Approved Phase 3,Phase 1,Phase 2 946414-94-4
18
Trioxsalen Approved Phase 3 3902-71-4 5585
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
21
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
22
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
23 Analgesics Phase 3,Phase 2
24 Analgesics, Non-Narcotic Phase 3,Phase 2
25 Anti-Inflammatory Agents Phase 3,Phase 2
26 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2
27 Antipyretics Phase 3
28 Antirheumatic Agents Phase 3,Phase 2
29 Cyclooxygenase Inhibitors Phase 3,Phase 2
30 Fibrinolytic Agents Phase 3
31 Peripheral Nervous System Agents Phase 3,Phase 2
32 Platelet Aggregation Inhibitors Phase 3
33 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
34
s 1 (combination) Phase 3,Phase 2
35 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
36 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
37 Antimetabolites Phase 3,Phase 2,Phase 1
38 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
39 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
40 Micronutrients Phase 2, Phase 3,Phase 1
41 Trace Elements Phase 2, Phase 3,Phase 1
42 Vitamin B Complex Phase 2, Phase 3,Phase 1
43 Vitamins Phase 2, Phase 3,Phase 1
44 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
45 Antimitotic Agents Phase 3,Phase 2,Phase 1
46 Pharmaceutical Solutions Phase 3
47 Antidotes Phase 2, Phase 3,Phase 1
48 Hematinics Phase 2, Phase 3,Phase 1
49 Protective Agents Phase 2, Phase 3,Phase 1
50 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 237)

# Name Status NCT ID Phase Drugs
1 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
2 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
3 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
4 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
5 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
6 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
7 Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus Completed NCT00002897 Phase 3 cisplatin;fluorouracil
8 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3 cisplatin;fluorouracil
9 Surgery or Chemoradiation for Esophageal Cancer Completed NCT01032967 Phase 3
10 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
11 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3 cisplatin;fluorouracil
12 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3 cisplatin;5-FU;oxaliplatin;Folinic Acid
13 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
14 Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Recruiting NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
15 Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT02399306 Phase 3 nutrison;Docetaxel, cisplatin
16 Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma Recruiting NCT02611700 Phase 3 Nimotuzumab;Paclitaxel;Cisplatin;Placebo
17 A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT03430843 Phase 3 BGB-A317;Paclitaxel, or Docetaxel, or Irinotecan
18 A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer Recruiting NCT02459457 Phase 3 Paclitaxel and Cisplatin;Paclitaxel and Fluorouracil;Paclitaxel and Carboplatin
19 A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma Recruiting NCT02570893 Phase 3 Paclitaxel and carboplatin
20 Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma Recruiting NCT02395705 Phase 3 cisplatin and paclitaxel
21 A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma Recruiting NCT02409186 Phase 3 Nimotuzumab;chemoradiotherapy Paclitaxel;chemoradiotherapy Cisplatin
22 Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT02461043 Phase 3 paclitaxel; cisplatin
23 Improve the Treatment of Thoracic Esophageal Cancer Recruiting NCT01137123 Phase 3 adjuvant chemotherapy
24 Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer Recruiting NCT02607540 Phase 3
25 Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer Recruiting NCT02025036 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
26 The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy Recruiting NCT02604615 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
27 Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer Recruiting NCT02465736 Phase 3 Docetaxel;Cisplatin;Vinorelbine;Cisplatin
28 Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Recruiting NCT01745107 Phase 3
29 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Recruiting NCT02564263 Phase 3 paclitaxel;docetaxel;irinotecan
30 Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer Recruiting NCT02891083 Phase 3 Adjuvant chemotherapy (Paclitaxel and Cisplatin)
31 Effect of Megestrol Acetate on the Quality of Life of Patients With Esophageal Carcinoma Recruiting NCT02644408 Phase 3 Megestrol(Yining)
32 Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy Recruiting NCT02603159 Phase 3 Capecitabine(Aibin)
33 S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer Recruiting NCT02813967 Phase 3 S-1
34 Robot Assisted Thoraco-Laparoscopic Esophagectomy Versus Conventional Thoraco-Laparoscopic Esophagectomy Recruiting NCT03094351 Phase 3
35 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Recruiting NCT03143153 Phase 3 Cisplatin;Fluorouracil
36 Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer Recruiting NCT02556762 Phase 3 PF
37 Study of SHR-1210 Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal Cancer Recruiting NCT03099382 Phase 3 Docetaxel;Irinotecan
38 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3 photosensitizer(photofrin)
39 A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma Active, not recruiting NCT01591135 Phase 3 Paclitaxel plus 5-fluorouracil;Cisplatin plus 5-fluorouracil
40 Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer Active, not recruiting NCT01216527 Phase 3
41 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Active, not recruiting NCT01107639 Phase 3 cisplatin;docetaxel
42 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Active, not recruiting NCT00655876 Phase 3 cisplatin;paclitaxel
43 Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin Not yet recruiting NCT03273647 Phase 3
44 Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC Not yet recruiting NCT03001596 Phase 3
45 Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma Suspended NCT02272699 Phase 2, Phase 3 Nimotuzumab;Paclitaxel;Cisplatin
46 Role of Esophagectomy in Complete Responders to CCRT Terminated NCT01740375 Phase 3
47 A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma Terminated NCT00190554 Phase 3 Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2;(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2+Surgery
48 RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus Terminated NCT00559351 Phase 3 neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)
49 Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer Terminated NCT01704690 Phase 2, Phase 3 S-1 and Paclitaxel;Paclitaxel and Cisplatin;5-FU and Cisplatin
50 Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Unknown status NCT02123381 Phase 2 cetuximab

Search NIH Clinical Center for Esophagus Squamous Cell Carcinoma

Cochrane evidence based reviews: esophageal squamous cell carcinoma

Genetic Tests for Esophagus Squamous Cell Carcinoma

Anatomical Context for Esophagus Squamous Cell Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Esophagus Squamous Cell Carcinoma:

18
The Esophagus

MalaCards organs/tissues related to Esophagus Squamous Cell Carcinoma:

38
Lymph Node, Lung, Endothelial, T Cells, Liver

Publications for Esophagus Squamous Cell Carcinoma

Articles related to Esophagus Squamous Cell Carcinoma:

(show all 12)
# Title Authors Year
1
Amplification and overexpression of CTTN and CCND1 at chromosome 11q13 in Esophagus squamous cell carcinoma (ESCC) of North Eastern Chinese Population. ( 27877079 )
2016
2
Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway. ( 26831667 )
2016
3
Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. ( 26814381 )
2016
4
Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. ( 23409141 )
2013
5
Human papillomavirus types 16 and 18 in esophagus squamous cell carcinoma: a meta-analysis. ( 23916383 )
2013
6
Prognostic Value of Tumor-Infiltrating Mast Cells in Outcome of Patients with Esophagus Squamous Cell Carcinoma. ( 24091743 )
2013
7
Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy. ( 23098537 )
2012
8
Prediagnostic smoking and postoperative survival in lymph node-negative esophagus squamous cell carcinoma patients. ( 22913634 )
2012
9
Dermatan sulfate is involved in the tumorigenic properties of esophagus squamous cell carcinoma. ( 22350411 )
2012
10
Analysis of the RUNX3 gene methylation in serum DNA from esophagus squamous cell carcinoma, gastric and colorectal adenocarcinoma patients. ( 22234069 )
2011
11
[Transforming growth factor beta1 regulation of epithelial-mesenchymal transition in esophagus squamous cell carcinoma]. ( 19094466 )
2008
12
Human papillomavirus DNA sequences in esophagus squamous cell carcinoma. ( 7912679 )
1994

Variations for Esophagus Squamous Cell Carcinoma

Expression for Esophagus Squamous Cell Carcinoma

Search GEO for disease gene expression data for Esophagus Squamous Cell Carcinoma.

Pathways for Esophagus Squamous Cell Carcinoma

GO Terms for Esophagus Squamous Cell Carcinoma

Cellular components related to Esophagus Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi apparatus GO:0005794 8.92 CDH1 CTTN DSE WWOX

Biological processes related to Esophagus Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of Wnt signaling pathway GO:0030178 8.62 CCND1 WWOX

Sources for Esophagus Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....